These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 1688733

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.
    Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
    [Abstract] [Full Text] [Related]

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep 01; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 6. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA, Hum GJ, Sheehan WW, Ryden VM, Bateman JR.
    Cancer Treat Rep; 1983 May 01; 67(5):413-9. PubMed ID: 6342771
    [Abstract] [Full Text] [Related]

  • 7. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
    van Beek RD, Smit M, van den Heuvel-Eibrink MM, de Jong FH, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Weber RF, Pieters R, de Muinck Keizer-Schrama SM.
    Hum Reprod; 2007 Dec 01; 22(12):3215-22. PubMed ID: 17981817
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
    Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H.
    Acta Eur Fertil; 1983 Dec 01; 14(3):221-2. PubMed ID: 6199937
    [No Abstract] [Full Text] [Related]

  • 10. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Dec 01; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 11. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb 01; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

  • 12. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2002 Dec 15; 95(12):2534-8. PubMed ID: 12467067
    [Abstract] [Full Text] [Related]

  • 13. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG, Pieresca C, Cavanna L, Corbella F, Vallisa D, Federico M, Formisano R, Carotenuto M, Merli F, Callea V, Angrilli F, Silingardi V.
    Haematologica; 1996 Dec 15; 81(6):503-12. PubMed ID: 9009437
    [Abstract] [Full Text] [Related]

  • 14. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P.
    Eur J Cancer; 2005 May 15; 41(7):998-1006. PubMed ID: 15862748
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
    Brusamolino E, Lazzarino M, Morra E, Inverardi D, Merante S, Castelli G, Canevari A, Dornini G, Bernasconi C.
    Haematologica; 1989 May 15; 74(2):173-9. PubMed ID: 2473013
    [Abstract] [Full Text] [Related]

  • 16. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A, Gobbi P, Danova M, Giordano M, Pieresca C, Bertoloni D, Brugnatelli S, Ascari E.
    Haematologica; 1993 May 15; 78(1):44-8. PubMed ID: 7684012
    [Abstract] [Full Text] [Related]

  • 17. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun 15; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 18. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G.
    Cancer Res; 1982 Nov 15; 42(11):4309-20. PubMed ID: 6181867
    [Abstract] [Full Text] [Related]

  • 19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct 15; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 20. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar 15; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.